Dirk Sibbing on The Importance of ISAR-REACT 5 trial and 2020 ESC Guidelines for ACS
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Very impressive and important data published in EuroIntervention today, showing how impactful data from randomized trials can be…
In 2019, the randomized ISAR-REACT 5 trial demonstrated superiority of prasugrel over ticagrelor for treatment of ACS patients undergoing PCI
In consequence, the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation included a new COR IIa in preference for prasugrel for ACS-PCI
Then, an entire (!) country (Denmark) shifted treatment from routine use of ticagrelor over to prasugrel.
Results of this „real-life“ experiment are now published in Eurointervention
In 10,984 patients, prasugrel was associated with reduced 1-year rate of MACE (adjHR 0.67) and MI (adjHR 0.65), without differences in bleeding risk.
Risk reductions from randomized (ISAR-REACT 5) vs. observational data (Denmark) were very similar, thereby supporting current guideline recommendations
A great example for how impactful clinical trial data can be for the benefit of our patients.”
Read the full article here.
Article: Impact of shifting from routine use of ticagrelor to prasugrel in myocardial infarction patients after PCI: a nationwide cohort study
Authors: Mia Ravn Jacobsen, Peter Laursen Graversen, Reza Jabbari, Erik Lerkevang Grove, Charlotte Glinge, Lene Holmvang, Tobias Geisler, Lars Køber, Christian Torp-Pedersen, Thomas Engstrøm, Rikke Sørensen
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Nov 5, 2025, 04:08Omid Seidizadeh: Pleased to Announce the Establishment of EAHAD Working Group on VWD
-
Nov 5, 2025, 03:54Marilena Vrana: ''Plasma Powers Possibility'' Continues to Resonate Far Beyond an Awareness Week
-
Nov 5, 2025, 03:30Dirk Sibbing on The Importance of ISAR-REACT 5 trial and 2020 ESC Guidelines for ACS
-
Nov 5, 2025, 03:14Abrham Mulugeta Shares Insights on Tranexamic Acid: Exploring the WHO WOMAN Trial
-
Nov 5, 2025, 03:01Shivanand Kumatagi Delivered Session on ISBT 128 at KMC Manipal
-
Nov 4, 2025, 08:57Toluwalase Awoyemi: Digital Health Meets Maternal Heart Care
-
Nov 4, 2025, 08:53Rebecca Ahrens Nicklas Shares FDA Interactions on Interventional Genetics with The Rare Disease Community
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:57Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 4, 2025, 09:10OCCUPI Trial Analysis Highlights Benefits of OCT Guidance in ACS Patients
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Nov 4, 2025, 09:17HaemophiliaIRL Series Begins․ Advances in von Willebrand Disease Treatment
-
Nov 4, 2025, 09:14Exploring Molecular Pathways of Aging in Hematopoiesis․ FEBS Workshop 2025
-
Nov 4, 2025, 08:28Fritz Roth Thanks Supporters of Science Magazine Study Linking Genes to High Cholesterol and Heart Attack Risk
-
Nov 4, 2025, 08:22Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
-
Nov 4, 2025, 08:14Cristina Anton: Excited to Be Part of Women in Hematology!